(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 4.47% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.34%.
Gilead Sciences's revenue in 2026 is $30,457,000,000.On average, 32 Wall Street analysts forecast GILD's revenue for 2026 to be $38,483,248,190,580, with the lowest GILD revenue forecast at $36,235,209,494,565, and the highest GILD revenue forecast at $40,200,586,080,255. On average, 31 Wall Street analysts forecast GILD's revenue for 2027 to be $40,835,443,119,615, with the lowest GILD revenue forecast at $37,739,275,097,580, and the highest GILD revenue forecast at $43,829,934,818,940.
In 2028, GILD is forecast to generate $43,022,724,013,035 in revenue, with the lowest revenue forecast at $39,445,453,390,860 and the highest revenue forecast at $49,319,216,290,125.